Apellis Pharmaceuticals, Inc. (APLS) Institutional Ownership

Ownership Summary

According to SEC filings for the period ending September 2025, Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) is held by 269 institutional firms.

• The collective stake of institutional investors in Apellis Pharmaceuticals moved to 98.3% in September 2025, a shift down from the 105.3% reported for June 2025.
• Institutional share ownership changed by -5.05% QoQ, while the number of institutional owners saw an increase of 3.86% YoY.
• Of these 269 institutional investors, 136 increased their holdings in Apellis Pharmaceuticals, while 104 of them reduced positions, and 29 investors maintained their exposure.
• Collectively, institutional investors decreased their stake in Apellis Pharmaceuticals to 124.13Mn shares as of September 2025, a change that is down by 6.61Mn shares quarter on quarter and up 4.33Mn shares year over year.
• The top institutional stake in Apellis Pharmaceuticals as of September 30, 2025 belongs to Avoro Capital Advisors LLC, which owns 12.22Mn shares, or 9.68% of the company.
• Among the most significant buyers of Apellis Pharmaceuticals during September 2025 were JENNISON ASSOCIATES LLC (1.69Mn), Polar Capital Holdings Plc (1.30Mn), MILLENNIUM MANAGEMENT LLC (1.14Mn), Deep Track Capital, LP (1.00Mn), ING GROEP NV (866.20K).
• Leading sellers of Apellis Pharmaceuticals stock in September 2025 included EcoR1 Capital, LLC (8.45Mn), MARSHALL WACE, LLP (2.31Mn), AQR CAPITAL MANAGEMENT LLC (1.49Mn), UBS Group AG (1.31Mn), Point72 Asset Management, L.P. (1.05Mn).
• The top 10 institutional holders of Apellis Pharmaceuticals for the quarter ending September 2025 included Avoro Capital Advisors LLC (12.22Mn), VANGUARD GROUP INC (9.99Mn), MORGAN STANLEY (9.64Mn), WELLINGTON MANAGEMENT GROUP LLP (9.29Mn), Deep Track Capital, LP (8.00Mn), BlackRock, Inc. (6.27Mn), AQR CAPITAL MANAGEMENT LLC (4.49Mn), JENNISON ASSOCIATES LLC (4.35Mn), STATE STREET CORP (4.04Mn), EcoR1 Capital, LLC (3.45Mn).